Endomag

At Endomag, we focus on the pressing challenges faced by breast cancer patients and their healthcare providers. Each year, millions of women are diagnosed with breast cancer, and most will undergo surgery as part of their treatment. Our mission is to improve breast cancer treatment by developing technologies that enable physicians to provide the highest standard of cancer care. Our products, including the Sentimag® probe, Magseed® marker, and Magtrace® lymphatic mapping agent, help ensure that women can avoid unnecessary surgery when it isn’t needed and experience better outcomes when surgery is necessary.

Founded in 2007 as a spin-out from the prestigious University College London and the University of Houston, we have evolved from an academic endeavor into a global leader in medical technology dedicated to improving breast cancer care. Today, over 1,350 hospitals across more than 45 countries utilize our technologies, helping a diverse population of women worldwide access more precise and less invasive treatment options. Our acquisition by Hologic in 2024 has further enhanced our capacity to advocate for breast cancer patients, enabling us to support healthcare professionals and expand access to critical resources in the fight against cancer.